Alkermes plc
ALKS
Helyezés a részvények között
#2637
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Részvényárfolyam
$43.05
Piaci kapitalizáció
$7.22B
Változás (1 nap)
4.43%
Változás (1 év)
42.25%
Ország
IE
Kereskedés Alkermes plc (ALKS)
Kategória
Healthcare
Alkermes plc (ALKS) nyeresége
Nyereség ekkor: Jun 2026 TTM: $97.32M
Alkermes plc legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $97.32M. 2023 évben a vállalat $421.52M nyereséget ért el, növekedés a 2022 év nyereségéhez, amely $-31.13M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Alkermes plc nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $97.32M | -78.07% |
| 2024 | $443.75M | 5.27% |
| 2023 | $421.52M | -1,454.15% |
| 2022 | $-31.13M | -135.48% |
| 2021 | $87.73M | -190.87% |
| 2020 | $-96.54M | -51.01% |
| 2019 | $-197.06M | 55.20% |
| 2018 | $-126.97M | -11.38% |
| 2017 | $-143.27M | -33.17% |
| 2016 | $-214.39M | -4.29% |
| 2015 | $-224.01M | 1,496.73% |
| 2014 | $-14.03M | -139.58% |
| 2013 | $35.44M | 0.00% |
| 2012 | $35.44M | -130.98% |
| 2011 | $-114.39M | 146.05% |
| 2010 | $-46.49M | 4.00% |
| 2009 | $-44.70M | -134.12% |
| 2008 | $131.01M | -24.20% |
| 2007 | $172.83M | 1,539.29% |
| 2006 | $10.54M | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-75.17M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-106.90M | 74.23% |
| 2001 | $-61.35M | 263.71% |
| 2000 | $-16.87M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $5.27B | 5,320.16% |
US
|
|
| $-3.09B | -3,272.01% |
US
|
|
| $-4.02B | -4,226.79% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,904.37% |
NL
|
